rxstat › Classes › Insulins And Analogues

Insulins And Analogues: shortage status in Canada

2 of the 14 insulins and analogues rxstat tracks are currently in shortage in Canada. When one drug in a class is short, demand often shifts to its alternatives, so related drugs can tighten too; each page below shows which manufacturers are affected and the latest recovery estimates.

Insulin Aspart (Fiasp) Partial shortage 1 of 8 reported products affected · est. return Jul 31, 2026 Insulin Glargine (Lantus) Partial shortage 1 of 6 reported products affected · est. return Jul 31, 2026 Insulin Glulisine (Apidra) Shortage anticipated 0 of 3 reported products affected Insulin Lispro (Admelog) Shortage anticipated 0 of 5 reported products affected Insulin (Myxredlin) No current shortage Insulin Detemir (Levemir Penfill) Discontinued 0 of 2 reported products affected Insulin Injection Human Biosynthetic (Novolin Ge Toronto Penfill) No current shortage Insulin Injection Pork Discontinued 0 of 1 reported products affected Insulin Isophane (Humulin) Discontinued 0 of 1 reported products affected Insulin Isophane Human Biosynthetic (Novolin Ge Nph Penfill) Discontinued 0 of 1 reported products affected Insulin Isophane Human Biosynthetic Injection (Novolin Ge) Discontinued 0 of 3 reported products affected Insulin Isophane Injection Pork Discontinued 0 of 1 reported products affected Insulin Nph Human Dna Origin (Humulin N) Discontinued 0 of 1 reported products affected Insulin Semi Synthetic Human (Humulin R) Discontinued 0 of 1 reported products affected

Guides: what to do when your medication is in shortage · how to read these statuses

Class groupings follow the WHO ATC classification in Health Canada's reports. Data reflects manufacturer mandatory filings; see methodology.